Polpharma is the leader of the Polish pharmaceutical market and one of the leading drug manufacturers in Central and Eastern Europe, with origins dating to 1935. Produces 400 million packages annually across 5 manufacturing plants and 3 R&D centers. The group includes Polpharma API (CDMO/API manufacturing), Polpharma Biologics (state-of-the-art biologic manufacturing including biosimilars and innovative molecules), and Farmaprojects (B2B hub). Has received grants for RNA-based medicines development under the STEP initiative. FDA registered for API manufacture.
Large-scale pharmaceutical manufacturing, API production, biosimilar development and manufacturing, RNA-based medicine research, generic drug development
2 sites worldwide
No reviews available yet.
No documents available.